These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12238451)

  • 1. Anti-HIV agents. Tenofovir and Videx (ddi) EC--some caution required.
    TreatmentUpdate; 2002 Aug; 14(6):5. PubMed ID: 12238451
    [No Abstract]   [Full Text] [Related]  

  • 2. Tenofovir drug interactions: ddI and d4T.
    TreatmentUpdate; 2003; 15(2):7. PubMed ID: 12693363
    [No Abstract]   [Full Text] [Related]  

  • 3. [No comparison with NRTI. Tenofovir is robust against resistance trouble].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():65. PubMed ID: 12043079
    [No Abstract]   [Full Text] [Related]  

  • 4. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine.
    Rollot F; Nazal EM; Chauvelot-Moachon L; Kélaïdi C; Daniel N; Saba M; Abad S; Blanche P
    Clin Infect Dis; 2003 Dec; 37(12):e174-6. PubMed ID: 14689363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome.
    Schaaf B; Aries SP; Kramme E; Steinhoff J; Dalhoff K
    Clin Infect Dis; 2003 Aug; 37(3):e41-3. PubMed ID: 12884188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rate of virologic failure with once-daily ddI/3TC/TDF.
    IAPAC Mon; 2003 Nov; 9(11):279. PubMed ID: 14989185
    [No Abstract]   [Full Text] [Related]  

  • 7. Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].
    Blanchard JN; Wohlfeiler M; Canas A; King K; Lonergan JT
    Clin Infect Dis; 2003 Sep; 37(5):e57-62. PubMed ID: 12942419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. French investigators warn of LPV/TDF/ddI interaction.
    Carter M
    IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
    [No Abstract]   [Full Text] [Related]  

  • 9. [First nucleotide analog on the market. New drug for the pretreated patient].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():84. PubMed ID: 12043094
    [No Abstract]   [Full Text] [Related]  

  • 10. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
    Tung MY; Mandalia S; Bower M; Gazzard B; Nelson M
    HIV Med; 2005 May; 6(3):151-4. PubMed ID: 15876280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tenofovir on didanosine absorption in patients with HIV.
    Pecora Fulco P; Kirian MA
    Ann Pharmacother; 2003 Sep; 37(9):1325-8. PubMed ID: 12921517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir and didanosine: a dangerous liaison.
    Waters L; Maitland D; Moyle GJ
    AIDS Read; 2005 Aug; 15(8):403-6, 413. PubMed ID: 16110555
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-HIV agents. Tenofovir looks good in initial therapy.
    TreatmentUpdate; 2002 Aug; 14(6):3-5. PubMed ID: 12238450
    [No Abstract]   [Full Text] [Related]  

  • 14. [Further indications for tenofovir].
    Dtsch Med Wochenschr; 2003 Sep; 128(39):2037. PubMed ID: 14565207
    [No Abstract]   [Full Text] [Related]  

  • 15. Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
    Lowe SH; van Leeuwen E; Droste JA; van der Veen F; Reiss P; Lange JM; Burger DM; Repping S; Prins JM
    Ther Drug Monit; 2007 Oct; 29(5):566-70. PubMed ID: 17898645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tenofovir--a new option for combination therapy].
    Polk B
    Med Monatsschr Pharm; 2002 Apr; 25(4):140-1. PubMed ID: 12017127
    [No Abstract]   [Full Text] [Related]  

  • 17. [Tenofovir (Viread)].
    Sidahora; 2002; (1):20-1. PubMed ID: 12772661
    [No Abstract]   [Full Text] [Related]  

  • 18. Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
    Anderson PL; Kakuda TN
    J Antimicrob Chemother; 2006 Jul; 58(1):220-1. PubMed ID: 16717052
    [No Abstract]   [Full Text] [Related]  

  • 19. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
    Miller MD; Margot N; Lu B; Zhong L; Chen SS; Cheng A; Wulfsohn M
    J Infect Dis; 2004 Mar; 189(5):837-46. PubMed ID: 14976601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure.
    Rifkin BS; Perazella MA
    Am J Med; 2004 Aug; 117(4):282-4. PubMed ID: 15308442
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.